[March 27, 2017]

SHAREHOLDER ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit against Aratana Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

Goldberg Law PC, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Aratana Therapeutics, Inc. ("Aratana" or the "Company") (Nasdaq: PETX). Investors who purchased or otherwise acquired Aratana shares between March 16, 2015 and February 3, 2017 inclusive (the "Class Period") are encouraged to contact the firm in advance of the April 7, 2017 lead plaintiff motion deadline.

If you are a shareholder who suffered a loss during the Class Period, click here to participate. In addition, we encourage you to contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 1999 Avenue of the Stars, Suite 1100, Los Angeles, CA (News - Alert) 9006, at 800-977-7401, to discuss your rights free of charge. You can also reach us through the firm's website at http://www.Goldberglawpc.com, or by email at [email protected].

The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

The Complaint alleges that throughout the Class Period, the Company made false and/or misleading statements and/or failed to disclose that: Aratana did not have manufacturing contracts in place sufficient to support manufacturing of its appetite stimulation drug ENTYCE at a commercial scale; ENTYCE was not likely to be commercially available until late 2017; the Company had misled investors with respect to the likely timeline for a commercial launch of ENTYCE; and that as a result of the above, Aratana's public statements were materially false and misleading at all relevant times. On February 6, 2017, the Company disclosed that the Center for Veterinary Medicine requested more information about ENTYCE. Aratana told investors that it "now anticipates that ENTYCE . . . will be commercially available by late 2017" and that the CVM's demand was "in connection with the Company's post-approval supplement request to transfer the manufacturing of ENTYCE to a new vendor in order to produce ENTYCE at a commercial scale." When this information was revealed to the investing public, the value of Aratana shares declined, causing investors severe harm.

Goldberg Law PC represents shareholders around the world and specializes in securities class actions and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170327005961/en/

[ Back To TMCnet.com's Homepage ]